PMID- 16965685
OWN - NLM
STAT- MEDLINE
DCOM- 20090528
LR  - 20151119
VI  - 25
IP  - 8
DP  - 2006 Aug
TI  - [Feasibility study of application of international prognostic score on prediction 
      of prognosis for advanced Hodgkin's lymphoma].
PG  - 1013-8
AB  - BACKGROUND & OBJECTIVE: Currently, 60% patients with advanced Hodgkin's lymphoma 
      could be cured by receiving standard treatments. The international prognostic 
      factor project on advanced Hodgkin's lymphoma has developed a concept of 
      international prognostic score (IPS) based on seven adverse prognostic factors 
      consisting of male sex, age 45 years or older, stage IV disease, leukocytosis, 
      lymphocytopenia, low hemoglobin and low serum albumin for newly diagnosed 
      advanced Hodgkin's lymphoma patients. This study was to explore the feasibility 
      of the international prognostic score in advanced Hodgkin's lymphoma. METHODS: We 
      performed a retrospective review of 141 patients with untreated advanced 
      Hodgkin's lymphoma in Cancer Center of Sun Yat-sen University between January 
      1980 and December 2004. IPS was defined as the number of adverse prognostic 
      factors presented at diagnosis. The rates of failure free survival (FFS) and 
      overall survival (OS) were estimated using the method of Kaplan-Meier and 
      compared according to IPS by log-rank test. Cox proportional hazard model was 
      used in multivariate analysis. RESULTS: The 5-year FFS and OS for 141 advanced 
      Hodgkin's lymphoma patients were 57.6%, 68.1% respectively. Estimated 5-year FFS 
      was 67.7%, 63.2%, 61.8%, 34.9% for patients with 0-1, 2, 3, > or =4 of the 
      adverse prognostic factors respectively. Estimated 5-year OS was 81.0%, 75.5%, 
      70.3%, 42.3% for patients with 0-1, 2, 3, > or =4 of the adverse prognostic 
      factors respectively. The 5-year FFS for low risk patients with IPS=0-2 and high 
      risk patients with IPS> or =3 were 65.4%, 48.9% respectively (log-rank test: 
      P=0.012); the 5 year OS for patients with IPS=0-2 and IPS> or =3 were 78.4%, 
      57.1% respectively (log-rank test: P=0.004). Low risk patients with IPS=0-2 had 
      superior overall survival than high risk patients with IPS> or =3 when treated 
      with ABVD or MOPP. The FFS and OS of the advanced HL patients at high risk 
      treated with ABVD were better than those treated with MOPP. Multivariate analysis 
      demonstrated that B symptoms, extranodal disease and MOPP chemotherapy were 
      independent adverse prognostic factors for FFS and OS. CONCLUSIONS: The IPS shows 
      good prognostic power in advanced HL. High risk advanced HL patients treated with 
      MOPP have inferior survival than those treated with ABVD, thus we recommend 
      patients to be treated with ABVD or more intensive regimen.
FAU - Fu, Xiao-Hong
AU  - Fu XH
AD  - State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. 
      R. China.
FAU - Wang, Shu-Sen
AU  - Wang SS
FAU - Huang, Yan
AU  - Huang Y
FAU - Wang, Bo
AU  - Wang B
FAU - Huang, Hui-Qiang
AU  - Huang HQ
FAU - Zhang, Li
AU  - Zhang L
FAU - Sun, Xiao-Fei
AU  - Sun XF
FAU - Xu, Rui-Hua
AU  - Xu RH
FAU - Lin, Tong-Yu
AU  - Lin TY
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 11056-06-7 (Bleomycin)
RN  - 35S93Y190K (Procarbazine)
RN  - 50D9XSG0VR (Mechlorethamine)
RN  - 5J49Q6B70F (Vincristine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - ABVD protocol
RN  - CHOP protocol
RN  - MOPP protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bleomycin/therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/therapeutic use
MH  - Dacarbazine/therapeutic use
MH  - Disease-Free Survival
MH  - Doxorubicin/therapeutic use
MH  - Feasibility Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Hodgkin Disease/*drug therapy/pathology/radiotherapy
MH  - Humans
MH  - Male
MH  - Mechlorethamine/therapeutic use
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prednisone/therapeutic use
MH  - Procarbazine/therapeutic use
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Vinblastine/therapeutic use
MH  - Vincristine/therapeutic use
MH  - Young Adult
EDAT- 2006/09/13 09:00
MHDA- 2009/05/29 09:00
CRDT- 2006/09/13 09:00
PHST- 2006/09/13 09:00 [pubmed]
PHST- 2009/05/29 09:00 [medline]
PHST- 2006/09/13 09:00 [entrez]
AID - 1000-467X2006081013 [pii]
PST - ppublish
SO  - Ai Zheng. 2006 Aug;25(8):1013-8.